Zacks: Brokerages Anticipate ConforMIS Inc (NASDAQ:CFMS) to Announce -$0.12 Earnings Per Share
Equities analysts expect ConforMIS Inc (NASDAQ:CFMS) to announce ($0.12) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for ConforMIS’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.13). ConforMIS reported earnings per share of ($0.24) in the same quarter last year, which would indicate a positive year-over-year growth rate of 50%. The company is scheduled to issue its next quarterly earnings results after the market closes on Wednesday, July 31st.
According to Zacks, analysts expect that ConforMIS will report full-year earnings of ($0.43) per share for the current fiscal year, with EPS estimates ranging from ($0.45) to ($0.39). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.33) per share, with EPS estimates ranging from ($0.37) to ($0.30). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for ConforMIS.
ConforMIS (NASDAQ:CFMS) last posted its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of $20.64 million during the quarter, compared to the consensus estimate of $20.11 million. ConforMIS had a negative return on equity of 97.85% and a negative net margin of 42.90%.
In other news, major shareholder Archon Capital Management Llc sold 164,796 shares of the stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $3.21, for a total value of $528,995.16. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Mark A. Augusti sold 23,860 shares of the stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $4.15, for a total value of $99,019.00. Following the completion of the sale, the chief executive officer now directly owns 1,093,031 shares in the company, valued at $4,536,078.65. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,317,864 shares of company stock worth $4,348,455. Insiders own 3.38% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new stake in shares of ConforMIS in the second quarter worth $44,000. Larson Financial Group LLC grew its stake in shares of ConforMIS by 588.6% in the first quarter. Larson Financial Group LLC now owns 24,100 shares of the medical instruments supplier’s stock worth $69,000 after acquiring an additional 20,600 shares during the last quarter. Cornerstone Advisory LLC purchased a new stake in shares of ConforMIS in the first quarter worth $72,000. CAPROCK Group Inc. grew its stake in shares of ConforMIS by 300.0% in the first quarter. CAPROCK Group Inc. now owns 80,000 shares of the medical instruments supplier’s stock worth $230,000 after acquiring an additional 60,000 shares during the last quarter. Finally, Joseph P. Lucia & Associates LLC purchased a new stake in shares of ConforMIS in the first quarter worth $45,100,000. 34.11% of the stock is currently owned by hedge funds and other institutional investors.
CFMS traded up $0.20 during trading on Friday, reaching $2.78. The stock had a trading volume of 812,256 shares, compared to its average volume of 1,565,443. The firm’s 50 day simple moving average is $3.86. The company has a quick ratio of 2.33, a current ratio of 3.00 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $175.09 million, a P/E ratio of -3.76 and a beta of 2.30. ConforMIS has a one year low of $0.36 and a one year high of $4.83.
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Featured Article: How to Invest in the Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.